The DOI matches its Crossref record; 104 of the 106 references it cites were found in a registry or an index; 23 of the 73 sources its claims cite were checked for support.
Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
Open accessAbstract
BACKGROUND: Global evaluations of the progress towards the WHO End TB Strategy 2020 interim milestones on mortality (35% reduction) and incidence (20% reduction) have not been age specific. We aimed to assess global, regional, and national-level burdens of and trends in tuberculosis and its risk factors across five separate age groups, from 1990 to 2021, and to report on age-specific progress between 2015 and 2020. METHODS: We used the Global Burden of Diseases, Injuries, and Risk Factors Study 2021 (GBD 2021) analytical framework to compute age-specific tuberculosis mortality and incidence estimates for 204 countries and territories (1990-2021 inclusive). We quantified tuberculosis mortality among individuals without HIV co-infection using 22 603 site-years of vital registration data, 1718 site-years of verbal autopsy data, 825 site-years of sample-based vital registration data, 680 site-years of mortality surveillance data, and 9 site-years of minimally invasive tissue sample (MITS) diagnoses data as inputs into the Cause of Death Ensemble modelling platform. Age-specific HIV and tuberculosis deaths were established with a population attributable fraction approach. We analysed all available population-based data sources, including prevalence surveys, annual case notifications, tuberculin surveys, and tuberculosis mortality, in DisMod-MR 2.1 to produce internally consistent age-specific estimates of tuberculosis incidence, prevalence, and mortality. We also estimated age-specific tuberculosis mortality without HIV co-infection that is attributable to the independent and combined effects of three risk factors (smoking, alcohol use, and diabetes). As a secondary analysis, we examined the potential impact of the COVID-19 pandemic on tuberculosis mortality without HIV co-infection by comparing expected tuberculosis deaths, modelled with trends in tuberculosis deaths from 2015 to 2019 in vital registration data, with observed tuberculosis deaths in 2020 and 2021 for countries with available cause-specific mortality data. FINDINGS: We estimated 9·40 million (95% uncertainty interval [UI] 8·36 to 10·5) tuberculosis incident cases and 1·35 million (1·23 to 1·52) deaths due to tuberculosis in 2021. At the global level, the all-age tuberculosis incidence rate declined by 6·26% (5·27 to 7·25) between 2015 and 2020 (the WHO End TB strategy evaluation period). 15 of 204 countries achieved a 20% decrease in all-age tuberculosis incidence between 2015 and 2020, eight of which were in western sub-Saharan Africa. When stratified by age, global tuberculosis incidence rates decreased by 16·5% (14·8 to 18·4) in children younger than 5 years, 16·2% (14·2 to 17·9) in those aged 5-14 years, 6·29% (5·05 to 7·70) in those aged 15-49 years, 5·72% (4·02 to 7·39) in those aged 50-69 years, and 8·48% (6·74 to 10·4) in those aged 70 years and older, from 2015 to 2020. Global tuberculosis deaths decreased by 11·9% (5·77 to 17·0) from 2015 to 2020. 17 countries attained a 35% reduction in deaths due to tuberculosis between 2015 and 2020, most of which were in eastern Europe (six countries) and central Europe (four countries). There was variable progress by age: a 35·3% (26·7 to 41·7) decrease in tuberculosis deaths in children younger than 5 years, a 29·5% (25·5 to 34·1) decrease in those aged 5-14 years, a 15·2% (10·0 to 20·2) decrease in those aged 15-49 years, a 7·97% (0·472 to 14·1) decrease in those aged 50-69 years, and a 3·29% (-5·56 to 9·07) decrease in those aged 70 years and older. Removing the combined effects of the three attributable risk factors would have reduced the number of all-age tuberculosis deaths from 1·39 million (1·28 to 1·54) to 1·00 million (0·703 to 1·23) in 2020, representing a 36·5% (21·5 to 54·8) reduction in tuberculosis deaths compared to those observed in 2015. 41 countries were included in our analysis of the impact of the COVID-19 pandemic on tuberculosis deaths without HIV co-infection in 2020, and 20 countries were included in the analysis for 2021. In 2020, 50 900 (95% CI 49 700 to 52 400) deaths were expected across all ages, compared to an observed 45 500 deaths, corresponding to 5340 (4070 to 6920) fewer deaths; in 2021, 39 600 (38 300 to 41 100) deaths were expected across all ages compared to an observed 39 000 deaths, corresponding to 657 (-713 to 2180) fewer deaths. INTERPRETATION: Despite accelerated progress in reducing the global burden of tuberculosis in the past decade, the world did not attain the first interim milestones of the WHO End TB Strategy in 2020. The pace of decline has been unequal with respect to age, with older adults (ie, those aged >50 years) having the slowest progress. As countries refine their national tuberculosis programmes and recalibrate for achieving the 2035 targets, they could consider learning from the strategies of countries that achieved the 2020 milestones, as well as consider targeted interventions to improve outcomes in older age groups. FUNDING: Bill & M
Overview
CoChat Summary
TL;DR
In GBD 2021, global tuberculosis incidence fell by 6·26% and tuberculosis deaths by 11·9% between 2015 and 2020, missing the WHO End TB Strategy 2020 milestones of 20% incidence reduction and 35% mortality reduction. Progress was unequal by age, with older adults improving slowest, while removing smoking, alcohol use, and diabetes would have reduced 2020 tuberculosis deaths by 36·5% versus 2015.
Key findings
- In 2021, there were an estimated 9·40 million (95% UI 8·36–10·5) tuberculosis incident cases and 1·35 million (1·23–1·52) tuberculosis deaths; HIV–tuberculosis co-infection accounted for 1·00 million (0·90–1·13) incident cases and 205 000 (158 000–248 000) deaths.
- From 2015 to 2020, the global all-age tuberculosis incidence rate declined by 6·26% (5·27–7·25) and global tuberculosis deaths declined by 11·9% (5·77–17·0); 15 of 204 countries achieved a 20% decrease in all-age incidence, and the abstract reports 17 countries attained a 35% reduction in deaths (the results text reports 19 countries/territories achieving this milestone).
- Age-specific incidence declines from 2015 to 2020 were largest in children younger than 5 years (16·5% [14·8–18·4]) and those aged 5–14 years (16·2% [14·2–17·9]), versus 6·29% (5·05–7·70) in ages 15–49, 5·72% (4·02–7·39) in ages 50–69, and 8·48% (6·74–10·4) in ages ≥70; death declines were 35·3% (26·7–41·7), 29·5% (25·5–34·1), 15·2% (10·0–20·2), 7·97% (0·472–14·1), and 3·29% (–5·56 to 9·07), respectively.
- Removing the combined effects of smoking, alcohol use, and diabetes would have reduced all-age tuberculosis deaths from 1·39 million (1·28–1·54) to 1·00 million (0·703–1·23) in 2020, a 36·5% (21·5–54·8) reduction versus observed 2015 deaths; corresponding reductions were 31·0% (15·9–48·8) in ages 15–49, 40·5% (22·3–62·6) in ages 50–69, and 41·0% (25·4–62·0) in ages ≥70. In the COVID-19 secondary analysis, 41 countries had 50 900 expected versus 45 500 observed tuberculosis deaths without HIV co-infection in 2020 (5 340 [4 070–6 920] fewer), and 20 countries had 39 600 expected versus 39 000 observed in 2021 (657 [–713 to 2 180] fewer).
Methods
- GBD 2021 analytical framework was used to compute age-specific tuberculosis mortality and incidence estimates for 204 countries and territories from 1990 to 2021. Tuberculosis mortality without HIV co-infection was modelled with CODEm using 22 603 site-years of vital registration data, 1 718 site-years of verbal autopsy data, 825 site-years of sample-based vital registration data, 680 site-years of mortality surveillance data, and 9 site-years of minimally invasive tissue sample diagnoses; HIV–tuberculosis deaths were estimated with a population attributable fraction approach.
- Tuberculosis morbidity was modelled in DisMod-MR 2.1 using prevalence surveys, annual case notifications, tuberculin surveys, and tuberculosis mortality data to produce internally consistent age-specific incidence, prevalence, and mortality estimates; incidence for countries with low-quality cause-of-death data was predicted via a mortality-to-incidence ratio approach, and incidence was disaggregated by HIV status.
- Risk-factor analysis computed age-sex-specific population attributable fractions for smoking, alcohol consumption, and diabetes among adults without HIV co-infection, then derived risk-deleted mortality rates. The COVID-19 secondary analysis used quasi-Poisson regression on 2015–2019 vital registration data to predict expected tuberculosis deaths in 2020–21 for countries with available cause-specific mortality data, stratified by ages <65 years, ≥65 years, and all ages.
Limitations
- The paper states that the primary limitation is data availability, with gaps across countries, age groups, and years; in the absence of data, estimates depended on covariates, spatial relationships, and out-of-sample predictive validity, and data scarcity is reflected in larger uncertainty intervals, with particular triangulation challenges in sub-Saharan Africa.
- The paper states it could not quantify tuberculosis mortality attributable to all important risk factors, excluding indoor air pollution and malnutrition, nor burden attributable to social determinants such as poverty and educational attainment; PAF estimates assume causality without confounding, that exposure removal does not affect unrelated risk factors, and that feasible interventions exist, and Levin’s formula may be biased although bias is often small with adjusted relative risks.
- The paper states that the COVID-19 impact could not be fully quantified due to insufficient empirical evidence and was restricted to 41 countries with available data, limiting generalisability; the text also makes evident that GBD 2021 and WHO 2022 estimates diverged for 2020–21 because of different modelling assumptions, and the authors discuss possible misclassification of COVID-19 deaths as tuberculosis deaths as an unresolved issue.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
13 Valid · 0 Not valid · 36 Not checked · 127 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recent progress has been unimpressive, however, as global annual rates of decline in tuberculosis incidence over the past 10 years have ranged between 1% and 2%.3, 4”
§ Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021 > Introduction
What the sources say
- Partly supportedcites [3] 2018, Global, regional, and national burden of tuberculosis, 1990–2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study, Lancet Infect Dis sourceExperimental — accuracy not yet measured
The Results section, “Changes in the burden of tuberculosis over time,” reports a 1.3% annual decline in global age-standardised incidence among HIV-negative individuals from 2006 to 2016. The claim omits that population qualifier: the same section reports a 4.0% annual decline among HIV-positive individuals, so the paper does not establish a 1–2% rate for tuberculosis incidence overall. (LLM, conf=0.86)
- Partly supportedcites [4] Pan, 2020, The gap between global tuberculosis incidence and the first milestone of the WHO End Tuberculosis Strategy: an analysis based on the Global Burden of Disease 2017 database, Infect Drug Resist sourceExperimental — accuracy not yet measured
The Results report a global annual decline in TB incidence of 1.1%, which falls within the claimed 1%–2% range. But that figure covers 2015–2017, not the past 10 years; the Discussion also says the study analyzed only three years of data. No page numbers are available in our copy. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“most tuberculosis transmission among children occurs outside the household,62”
§ Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021 > Discussion
What the sources say
- Supportedcites [62] Martinez, 2019, Paediatric tuberculosis transmission outside the household: challenging historical paradigms to inform future public health strategies, Lancet Respir Med source
The Epidemiological evidence section states that, across 13 studies, most transmission to children occurs outside the household. The paper frames this conclusion particularly around high-burden settings. (LLM, conf=0.93)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“they are more likely to have adverse reactions to treatment.66”
§ Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021 > Discussion
What the sources say
- Partly supportedcites [66] Hosford, 2015, Hepatotoxicity from antituberculous therapy in the elderly: a systematic review, Tuberculosis sourceExperimental — accuracy not yet measured
The Discussion reports higher odds of TB-drug-associated hepatotoxic events in patients over 60 than in younger patients (OR 1.71, 95% CI 1.24–2.35). That supports an increased risk of a specific adverse reaction to antituberculous treatment, but the cited review does not establish that older individuals are more likely to have adverse reactions to treatment generally. Page numbers were not supplied in the passages. (LLM, conf=0.85)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This analysis provides some indication that previously described disruptions in tuberculosis services and treatment in both Russia78, 79 and Brazil80 might have led to increases in tuberculosis mortality.”
§ Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021 > Discussion
What the sources say
- Supportedcites [78] Migliori, 2021, Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study, Eur Respir J source
The cited study reports declines in TB diagnoses and care activity, including an evident decline in identified drug-resistant TB in Brazil (Abstract; page unavailable). In the citing sentence, this source supports the previously described disruptions; the suggestion that they might have increased mortality is framed as the citing authors’ own inference, not a finding attributed to this study. (LLM, conf=0.88)
- Partly supportedcites [79] Nalunjogi, 2023, Impact of COVID-19 on diagnosis of tuberculosis, multidrug-resistant tuberculosis, and on mortality in 11 countries in Europe, Northern America, and Australia. A Global Tuberculosis Network study, Int J Infect Dis sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) links disrupted TB services with reduced case-finding and higher TB mortality, supporting the general possibility in the claim. But the study's Results concern 11 countries in Europe, Northern America, and Australia; our copy does not document disruptions or mortality increases in Russia or Brazil. (LLM, conf=0.85)
- Supportedcites [80] Souza, 2022, Impact of the COVID-19 pandemic on the diagnosis of tuberculosis in Brazil: is the WHO End TB Strategy at risk?, Front Pharmacol source
The Discussion reports that pandemic-related changes to Brazilian health services reduced tuberculosis diagnosis and may have affected timely treatment, access to care, and treatment adherence. The citing authors present the possible increase in mortality as their own inference, not as a finding attributed to this source. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“HIV and tuberculosis co-infection constituted 1·00 million (0·90–1·13; 10·7% [10·3–11·0]) of the 9·40 million all-form tuberculosis incident cases and 205 000 (158 000–248 000; 15·1% [11·9–17·7]) of the 1·35 million all-form global tuberculosis deaths.”
§ Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021 > Results > Overview
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
96 more claims
Create a free account to see all 176 claims and to verify the 50 references still open.
- It may state two separate claims as one. 51
- Probably not a substantial claim. 38
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast to our analysis, which we based on the GHE, a recent Global Burden of Disease (GBD) study reported lower tuberculosis deaths during the pandemic compared to expected deaths.83”
From Global health 2050: the path to halving premature death by mid-century (2024) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021 > Results > Progress towards the End TB Strategy 2020 milestones
“19 countries and territories achieved this milestone: six in eastern Europe, four in central Europe, four in central Asia, two in the Caribbean, one in Andean Latin America, one in Australasia, and one in western sub-Saharan Africa”
§ Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021 > Abstract > Findings
“17 countries attained a 35% reduction in deaths due to tuberculosis between 2015 and 2020”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021 > Discussion
“we found negative excess tuberculosis deaths in both 2020 and 2021 when aggregating across 41 of 204 countries”
§ Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021 > Results > Impact of the COVID-19 pandemic on tuberculosis mortality
“There were 20 countries reporting data through the year 2021”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021 > Results > Progress towards the End TB Strategy 2020 milestones
“Furthermore, the cumulative number of countries achieving a 35% decrease would have increased from 15 to 132 in 2020 and 143 in 2021”
§ Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021 > Abstract > Findings
“17 countries attained a 35% reduction in deaths due to tuberculosis between 2015 and 2020”
Citations
Cites
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
Self-citationJames, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Self-citationMurray, C. J. L., Aravkin, A. Y., Zheng, P., Abbafati, C., Abbas, K. M., Abbasi-Kangevari, M., Abd-Allah, F., Abdelalim, A., Abdollahi, M., Abdollahpour, I., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30752-2 · Cited by 9,854
Self-citationOng, K. L., Stafford, L. K., McLaughlin, S. A., Boyko, E. J., Vollset, S. E., Smith, A. E., Dalton, B. E., Duprey, J., Cruz, J. A., Hagins, H., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01301-6 · Cited by 6,146
Self-citationWang, H., Paulson, K. R., Pease, S. A., Watson, S., Comfort, H., Zheng, P., Aravkin, A. Y., Bisignano, C., Barber, R. M., Alam, T., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02796-3 · Cited by 2,069 · cited 1×
“Although the Institute for Health Metrics and Evaluation has estimated that there were 18 million excess all-cause deaths for the years 2020–21, 108 there is a scarcity of data on what fraction of these, if any, are due to tuberculosis.”
Self-citationPerin, J., Mulick, A., Yeung, D., Villavicencio, F., Lopez, G., Strong, K. L., Prieto-Merino, D., Cousens, S., Black, R. E., & Liu, L. (2022) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(21)00311-4 · Cited by 1,667 · cited 1×
“11 The substantial progress in reducing the tuberculosis burden in children might reflect recent trends showing marked decreases in child mortality, 54 global improvements in child nutrition outcomes, 55,56 increasing tuberculosis case finding and services for children, 57–59 and continued…”
Uplekar, M., Weil, D., Lonnroth, K., Jaramillo, E., Lienhardt, C., Dias, H. M., Falzon, D., Floyd, K., Gargioni, G., Getahun, H., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60570-0 · Cited by 1,117
Gavazzi, G., & Krause, K.-H. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00437-1 · Cited by 990 · cited 2×
“11 Several factors could explain these marked age-related differences, including age-specific diagnostic challenges, 12,13 age-specific mixing patterns, 14 immune senescence 15 and other age-related immune dysfunctions, 16 and comorbidities common in older patients masking tuberculosis symptoms.”
Tiemersma, E. W., van der Werf, M. J., Borgdorff, M. W., Williams, B. G., & Nagelkerke, N. J. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017601 · Cited by 583 · cited 2×
“To further improve internal consistency of modelling in DisMod, we computed all-age and both-sexes priors of tuberculosis duration using a combination of tuberculosis duration data from a systematic review of studies during the pre-chemotherapy era 25 and the HAQ Index.”
Bryazka, D., Reitsma, M. B., Griswold, M. G., Abate, K. H., Abbafati, C., Abbasi-Kangevari, M., Abbasi-Kangevari, Z., Abdoli, A., Abdollahi, M., Abdullah, A. Y. M., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00847-9 · Cited by 582
Self-citation
Research works printed but not linked: 2
- Byng-Maddick, 2016, Does tuberculosis threaten our ageing populations?, BMC Infect Dis, 16, 119, 10.1186/s12879-016-1451-0 · DOI · Paper page
- Casco, 2023, Long-term outcomes of the global TB and COVID-19 coinfection cohort, Eur Respir J, 62
Cited by
Naghavi, M., Kyu, H. H., A, B., Aalipour, M. A., Aalruz, H., Ababneh, H. S., Abafita, B. J., Abaraogu, U. O., Abbafati, C., Abbasi, M., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01917-8 · Cited by 595
Self-citationOh, J., Kim, S., Kim, M. S., Abate, Y. H., Abd ElHafeez, S., Abdelkader, A., Abdi, P., Abdulah, D. M., Aboagye, R. G., Abolhassani, H., et al. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(25)00003-7 · Cited by 236
Self-citationXie, K., Cao, H., Ling, S., Zhong, J., Chen, H., Chen, P., & Huang, R. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1526482 · Cited by 147
Global health 2050: the path to halving premature death by mid-century
Jamison, D. T., Summers, L. H., Chang, A. Y., Karlsson, O., Mao, W., Norheim, O. F., Ogbuoji, O., Schäferhoff, M., Watkins, D., Adeyi, O., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01439-9 · Cited by 125
Self-citationOh, J. S., Kim, S., Yim, Y., Kim, M. S., Collaborators, G. 2. S. U., Shin, J. I., Jabbar, A. A., Aalruz, H., Abbasian, M., Magied, A. H. A. A. A., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04077-9 · Cited by 83
“Two previous studies have also reported a decrease in the incidence of non-COVID lower respiratory infections and tuberculosis during the COVID-19 pandemic 7,8 .”
Self-citation
Metadata
- Authors
- Ledesma, J. R., Ma, J., Zhang, M., Basting, A. V. L., Chu, H. T., Vongpradith, A., Novotney, A., LeGrand, K. E., Xu, Y. Y., Dai, X., Nicholson, S. I., Stafford, L. K., Carter, A., Ross, J. M., Abbastabar, H., Abdoun, M., Abdulah, D. M., Aboagye, R. G., Abolhassani, H., Abrha, W. A., Abubaker Ali, H., Abu-Gharbieh, E., Aburuz, S., Addo, I. Y., Adepoju, A. V., Adhikari, K., Adnani, Q. E. S., Adra, S., Afework, A., Aghamiri, S., Agyemang-Duah, W., Ahinkorah, B. O., Ahmad, D., Ahmad, S., Ahmadzade, A. M., Ahmed, H., Ahmed, M., Ahmed, A., Akinosoglou, K., AL-Ahdal, T. M. A., Alam, N., Albashtawy, M., AlBataineh, M. T., Al-Gheethi, A. A. S., Ali, A., Ali, E. A., Ali, L., Ali, Z., Ali, S. S. S., Allel, K., Altaf, A., Al-Tawfiq, J. A., Alvis-Guzman, N., Alvis-Zakzuk, N. J., Amani, R., Amusa, G. A., Amzat, J., Andrews, J. R., Anil, A., Anwer, R., Aravkin, A. Y., Areda, D., Artamonov, A. A., Aruleba, R. T., Asemahagn, M. A., Atre, S. R., Aujayeb, A., Azadi, D., Azadnajafabad, S., Azzam, A. Y., Badar, M., Badiye, A. D., Bagherieh, S., Bahadorikhalili, S., Baig, A. A., Banach, M., Banik, B., Bardhan, M., Barqawi, H. J., Basharat, Z., Baskaran, P., Basu, S., Beiranvand, M., Belete, M. A., Belew, M. A., Belgaumi, U. I., Beloukas, A., Bettencourt, P. J. G., Bhagavathula, A. S., Bhardwaj, N., Bhardwaj, P., Bhargava, A., Bhat, V., Bhatti, J. S., Bhatti, G. K., Bikbov, B., Bitra, V. R., Bjegovic-Mikanovic, V., Buonsenso, D., Burkart, K., Bustanji, Y., Butt, Z. A., Camargos, P., Cao, Y., Carr, S., Carvalho, F., Cegolon, L., Cenderadewi, M., Cevik, M., Chahine, Y., Chattu, V. K., Ching, P. R., Chopra, H., Chung, E., Claassens, M. M., Coberly, K., Cruz-Martins, N., Dabo, B., Dadana, S., Dadras, O., Darban, I., Darega Gela, J., Darwesh, A. M., Dashti, M., Demessa, B. H., Demisse, B., Demissie, S., Derese, A. M. A., Deribe, K., Desai, H. D., Devanbu, V. G. C., Dhali, A., Dhama, K., Dhingra, S., Do, T. H. P., Dongarwar, D., Dsouza, H. L., Dube, J., Dziedzic, A. M., Ed-Dra, A., Efendi, F., Effendi, D. E., Eftekharimehrabad, A., Ekadinata, N., Ekundayo, T. C., Elhadi, M., Elilo, L. T., Emeto, T. I., Engelbert Bain, L., Fagbamigbe, A. F., Fahim, A., Feizkhah, A., Fetensa, G., Fischer, F., Gaipov, A., Gandhi, A. P., Gautam, R. K., Gebregergis, M. W., Gebrehiwot, M., Gebrekidan, K. G., Ghaffari, K., Ghassemi, F., Ghazy, R. M., Goodridge, A., Goyal, A., Guan, S.-Y., Gudeta, M. D., Guled, R. A., Gultom, N. B., Gupta, V. B., Gupta, V. K., Gupta, S., Hagins, H., Hailu, S. G., Hailu, W. B., Hamidi, S., Hanif, A., Harapan, H., Hasan, R. S., Hassan, S., Haubold, J., Hezam, K., Hong, S. H., Horita, N., Hossain, M. B., Hosseinzadeh, M., Hostiuc, M., Hostiuc, S., Huynh, H.-H., Ibitoye, S. E., Ikuta, K. S., Ilic, I. M., Ilic, M. D., Islam, M. R., Ismail, N. E., Ismail, F., Jafarzadeh, A., Jakovljevic, M., Jalili, M., Janodia, M. D., Jomehzadeh, N., Jonas, J. B., Joseph, N., Joshua, C. E., Kabir, Z., Kamble, B. D., Kanchan, T., Kandel, H., Kanmodi, K. K., Kantar, R. S., Karaye, I. M., Karimi Behnagh, A., Kassa, G. G., Kaur, R. J., Kaur, N., Khajuria, H., Khamesipour, F., Khan, Y. H., Khan, M. N., Khan Suheb, M. Z., Khatab, K., Khatami, F., Kim, M. S., Kosen, S., Koul, P. A., Koulmane Laxminarayana, S. L., Krishan, K., Kucuk Bicer, B., Kuddus, M. A., Kulimbet, M., Kumar, N., Lal, D. K., Landires, I., Latief, K., Le, T. D. T., Le, T. T. T., Ledda, C., Lee, M., Lee, S. W., Lerango, T. L., Lim, S. S., Liu, C., Liu, X., Lopukhov, P. D., Luo, H., Lv, H., Mahajan, P. B., Mahboobipour, A. A., Majeed, A., Malakan Rad, E., Malhotra, K., Malik, M. S. A., Malinga, L. A., Mallhi, T. H., Manilal, A., Martinez-Guerra, B. A., Martins-Melo, F. R., Marzo, R. R., Masoumi-Asl, H., Mathur, V., Maude, R. J., Mehrotra, R., Memish, Z. A., Mendoza, W., Menezes, R. G., Merza, M. A., Mestrovic, T., Mhlanga, L., Misra, S., Misra, A. K., Mithra, P., Moazen, B., Mohammed, H., Mokdad, A. H., Monasta, L., Moore, C. E., Mousavi, P., Mulita, F., Musaigwa, F., Muthusamy, R., Nagarajan, A. J., Naghavi, P., Naik, G. R., Naik, G., Nair, S., Nair, T. S., Natto, Z. S., Nayak, B. P., Negash, H., Nguyen, D. H., Nguyen, V. T., Niazi, R. K., Nnaji, C. A., Nnyanzi, L. A., Noman, E. A., Nomura, S., Oancea, B., Obamiro, K. O., Odetokun, I. A., Odo, D. B. O., Odukoya, O. O., Oh, I.-H., Okereke, C. O., Okonji, O. C., Oren, E., Ortiz-Brizuela, E., Osuagwu, U. L., Ouyahia, A., P A, M. P., Parija, P. P., Parikh, R. R., Park, S., Parthasarathi, A., Patil, S., Pawar, S., Peng, M., Pepito, V. C. F., Peprah, P., Perdigão, J., Perico, N., Pham, H. T., Postma, M. J., Prabhu, A. R. A., Prasad, M., Prashant, A., Prates, E. J. S., Rahim, F., Rahman, M., Rahman, M. A., Rahmati, M., Rajaa, S., Ramasamy, S. K., Rao, I. R., Rao, S. J., Rapaka, D., Rashid, A. M., Ratan, Z. A., Ravikumar, N., Rawaf, S., Reddy, M. M. R. K., Redwan, E. M. M., Remuzzi, G., Reyes, L. F., Rezaei, N., Rezaeian, M., Rezahosseini, O., Rodrigues, M., Roy, P., Ruela, G. D. A., Sabour, S., Saddik, B., Saeed, U., Safi, S. Z., Saheb Sharif-Askari, N., Saheb Sharif-Askari, F., Sahebkar, A., Sahiledengle, B., Sahoo, S. S., Salam, N., Salami, A. A., Saleem, S., Saleh, M. A., Samadi Kafil, H., Samadzadeh, S., Samodra, Y. L., Sanjeev, R. K., Saravanan, A., Sawyer, S. M., Selvaraj, S., Senapati, S., Senthilkumaran, S., Shah, P. A., Shahid, S., Shaikh, M. A., Sham, S., Shamshirgaran, M. A., Shanawaz, M., Sharath, M., Sherchan, S. P., Shetty, R. S., Shirzad-Aski, H., Shittu, A., Siddig, E. E., Silva, J. P., Singh, S., Singh, P., Singh, H., Singh, J. A., Siraj, M. S., Siswanto, S., Solanki, R., Solomon, Y., Soriano, J. B., Sreeramareddy, C. T., Srivastava, V. K., Steiropoulos, P., Swain, C. K., Tabuchi, T., Tampa, M., Tamuzi, J. J. L., Tat, N. Y., Tavakoli Oliaee, R., Teklay, G., Tesfaye, E. G., Tessema, B., Thangaraju, P., Thapar, R., Thum, C. C. C., Ticoalu, J. H. V., Tleyjeh, I. M., Tobe-Gai, R., Toma, T. M., Tram, K. H., Udoakang, A. J., Umar, T. P., Umeokonkwo, C. D., Vahabi, S. M., Vaithinathan, A. G., van Boven, J. F. M., Varthya, S. B., Wang, Z., Warsame, M. S. A., Westerman, R., Wonde, T. E., Yaghoubi, S., Yi, S., Yiğit, V., Yon, D. K., Yonemoto, N., Yu, C., Zakham, F., Zangiabadian, M., Zeukeng, F., Zhang, H., Zhao, Y., Zheng, P., Zielińska, M., Salomon, J. A., Reiner Jr, R. C., Naghavi, M., Vos, T., Hay, S. I., Murray, C. J. L., & Kyu, H. H.
- Affiliations
- University of Washington (US)
- ORCID
- Ledesma, Jorge R
- Ma, Jianing
- Basting, Ann V L
- Novotney, Amanda
- LeGrand, Kate E
- Xu, Yvonne Yiru
- Dai, Xiaochen
- Stafford, Lauryn K
- Carter, Austin
- Ross, Jennifer M
- Abbastabar, Hedayat
- Abdoun, Meriem
- Abdulah, Deldar Morad
- Aboagye, Richard Gyan
- Abolhassani, Hassan
- Aburuz, Salahdein
- Addo, Isaac Yeboah
- Adhikari, Kishor
- Adnani, Qorinah Estiningtyas Sakilah
- Adra, Saryia
- Ahinkorah, Bright Opoku
- Ahmad, Danish
- Ahmadzade, Amir Mahmoud
- Ahmed, Haroon
- Ahmed, Mohammed
- Ahmed, Ayman
- Akinosoglou, Karolina
- AL-Ahdal, Tareq Mohammed Ali
- Alam, Nazmul
- Albashtawy, Mohammed
- Al-Gheethi, Adel Ali Saeed
- Ali, Abid
- Ali, Endale Alemayehu
- Ali, Liaqat
- Ali, Zahid
- Ali, Syed Shujait Shujait
- Allel, Kasim
- Altaf, Awais
- Alvis-Zakzuk, Nelson J.
- Amzat, Jimoh
- Andrews, Jason R
- Anil, Abhishek
- Anwer, Razique
- Aravkin, Aleksandr Y
- Artamonov, Anton A
- Aruleba, Raphael Taiwo
- Asemahagn, Mulusew A
- Atre, Sachin R
- Aujayeb, Avinash
- Azadi, Davood
- Azadnajafabad, Sina
- Azzam, Ahmed Y
- Badar, Muhammad
- Badiye, Ashish D
- Bagherieh, Sara
- Baig, Atif Amin
- Banach, Maciej
- Banik, Biswajit
- Bardhan, Mainak
- Barqawi, Hiba Jawdat
- Basharat, Zarrin
- Baskaran, Pritish
- Basu, Saurav
- Beiranvand, Maryam
- Belete, Melaku Ashagrie
- Belew, Makda Abate
- Belgaumi, Uzma Iqbal
- Beloukas, Apostolos
- Bettencourt, Paulo J G
- Bhagavathula, Akshaya Srikanth
- Bhardwaj, Nikha
- Bhardwaj, Pankaj
- Bhargava, Ashish
- Bhatti, Jasvinder Singh
- Bhatti, Gurjit Kaur
- Bikbov, Boris
- Bitra, Veera R
- Bjegovic-Mikanovic, Vesna
- Buonsenso, Danilo
- Burkart, Katrin
- Bustanji, Yasser
- Butt, Zahid A
- Camargos, Paulo
- Cao, Yu
- Carr, Sinclair
- Cegolon, Luca
- Cenderadewi, Muthia
- Chahine, Yaacoub
- Chattu, Vijay Kumar
- Ching, Patrick R
- Chopra, Hitesh
- Claassens, Mareli M
- Dadana, Sriharsha
- Dadras, Omid
- Darban, Isaac
- Darwesh, Aso Mohammad
- Demisse, Biniyam
- Demissie, Solomon
- Deribe, Kebede
- Desai, Hardik Dineshbhai
- Dhali, Arkadeep
- Dhama, Kuldeep
- Dhingra, Sameer
- Dongarwar, Deepa
- Dsouza, Haneil Larson
- Dube, John
- Dziedzic, Arkadiusz Marian
- Efendi, Ferry
- Effendi, Diyan Ermawan
- Ekadinata, Nopryan
- Ekundayo, Temitope Cyrus
- Elhadi, Muhammed
- Elilo, Legesse Tesfaye
- Emeto, Theophilus I
- Fagbamigbe, Adeniyi Francis
- Fahim, Ayesha
- Feizkhah, Alireza
- Fischer, Florian
- Gaipov, Abduzhappar
- Gandhi, Aravind P
- Gautam, Rupesh K
- Gebrehiwot, Mesfin
- Gebrekidan, Kahsu Gebrekirstos
- Ghaffari, Kazem
- Ghassemi, Fariba
- Ghazy, Ramy Mohamed
- Goodridge, Amador
- Guan, Shi-Yang
- Guled, Rashid Abdi
- Gultom, Novianti Br
- Gupta, Veer Bala
- Gupta, Vivek Kumar
- Gupta, Sapna
- Hailu, Semira Goitom
- Hailu, Wase Benti
- Hamidi, Samer
- Hanif, Asif
- Harapan, Harapan
- Hasan, Rumina Syeda
- Haubold, Johannes
- Hezam, Kamal
- Hong, Sung Hwi
- Horita, Nobuyuki
- Hossain, Md. Belal
- Hosseinzadeh, Mehdi
- Hostiuc, Mihaela
- Hostiuc, Sorin
- Huynh, Hong-Han
- Ibitoye, Segun Emmanuel
- Ikuta, Kevin S
- Islam, Md. Rabiul
- Ismail, Nahlah Elkudssiah
- Ismail, Faisal
- Jafarzadeh, Abdollah
- Janodia, Manthan Dilipkumar
- Jomehzadeh, Nabi
- Jonas, Jost B
- Joseph, Nitin
- Kabir, Zubair
- Kamble, Bhushan Dattatray
- Kanchan, Tanuj
- Kandel, Himal
- Kanmodi, Kehinde Kazeem
- Kantar, Rami S
- Karaye, Ibraheem M
- Kassa, Gebrehiwot G
- Kaur, Rimple Jeet
- Kaur, Navjot
- Khajuria, Himanshu
- Khamesipour, Faham
- Khan, M Nuruzzaman
- Khatab, Khaled
- Kim, Min Seo
- Kosen, Soewarta
- Koul, Parvaiz A
- Krishan, Kewal
- Kuddus, Md Abdul
- Kulimbet, Mukhtar
- Kumar, Nithin
- Landires, Iván
- Latief, Kamaluddin
- Le, Trang Diep Thanh
- Ledda, Caterina
- Lee, Munjae
- Lee, Seung Won
- Lerango, Temesgen L
- Lim, Stephen S
- Liu, Chaojie
- Liu, Xuefeng
- Luo, Hong
- Mahajan, Preetam Bhalchandra
- Mahboobipour, Amir Ali
- Majeed, Azeem
- Malhotra, Kashish
- Malik, Muhammad Sajeel Ahmed
- Malinga, Lesibana Anthony
- Mallhi, Tauqeer Hussain
- Manilal, Aseer
- Marzo, Roy Rillera
- Masoumi-Asl, Hossein
- Mathur, Vasundhara
- Maude, Richard James
- Mehrotra, Ravi
- Memish, Ziad A
- Menezes, Ritesh G
- Merza, Muayad Aghali
- Mhlanga, Laurette
- Misra, Sanjeev
- Misra, Arup Kumar
- Mithra, Prasanna
- Moazen, Babak
- Mohammed, Hussen
- Mokdad, Ali H
- Monasta, Lorenzo
- Moore, Catrin E
- Mousavi, Parsa
- Mulita, Francesk
- Musaigwa, Fungai
- Nagarajan, Ahamarshan Jayaraman
- Naghavi, Pirouz
- Naik, Ganesh R
- Naik, Gurudatta
- Nair, Sanjeev
- Nair, Tapas Sadasivan
- Natto, Zuhair S
- Nayak, Biswa Prakash
- Nguyen, Dang H
- Nnaji, Chukwudi A
- Nnyanzi, Lawrence Achilles
- Noman, Efaq Ali
- Nomura, Shuhei
- Oancea, Bogdan
- Obamiro, Kehinde O
- Odetokun, Ismail A
- Odo, Daniel Bogale Odo
- Odukoya, Oluwakemi Ololade
- Oh, In-Hwan
- Okonji, Osaretin Christabel
- Oren, Eyal
- Osuagwu, Uchechukwu Levi
- Ouyahia, Amel
- Parija, Pragyan Paramita
- Parikh, Romil R
- Park, Seoyeon
- Parthasarathi, Ashwaghosha
- Patil, Shankargouda
- Pawar, Shrikant
- Peng, Minjin
- Pepito, Veincent Christian Filipino
- Peprah, Prince
- Perdigão, João
- Perico, Norberto
- Pham, Hoang Tran
- Postma, Maarten J
- Prasad, Manya
- Prashant, Akila
- Prates, Elton Junio Sady
- Rahim, Fakher
- Rahman, Mosiur
- Rahman, Muhammad Aziz
- Rahmati, Masoud
- Rajaa, Sathish
- Ramasamy, Shakthi Kumaran
- Rao, Indu Ramachandra
- Rapaka, Deepthi
- Rashid, Ahmed Mustafa
- Ratan, Zubair Ahmed
- Ravikumar, Nakul
- Rawaf, Salman
- Remuzzi, Giuseppe
- Reyes, Luis Felipe
- Rezaei, Nazila
- Rezaeian, Mohsen
- Rezahosseini, Omid
- Rodrigues, Mónica
- Roy, Priyanka
- Ruela, Guilherme de Andrade
- Sabour, Siamak
- Saddik, Basema
- Saeed, Umar
- Safi, Sher Zaman
- Sahebkar, Amirhossein
- Sahiledengle, Biniyam
- Sahoo, Soumya Swaroop
- Salam, Nasir
- Salami, Afeez Abolarinwa
- Saleem, Samreen
- Saleh, Mohamed A
- Samadzadeh, Sara
- Samodra, Yoseph Leonardo
- Sanjeev, Rama Krishna
- Saravanan, Aswini
- Sawyer, Susan M
- Selvaraj, Siddharthan
- Senapati, Sabyasachi
- Senthilkumaran, Subramanian
- Shah, Pritik A
- Shahid, Samiah
- Shaikh, Masood Ali
- Shamshirgaran, Mohammad Ali
- Sharath, Medha
- Sherchan, Samendra P
- Shetty, Ranjitha S
- Shittu, Aminu
- Siddig, Emmanuel Edwar
- Silva, João Pedro
- Singh, Surjit
- Singh, Paramdeep
- Singh, Harpreet
- Siraj, Md Shahjahan
- Siswanto, Siswanto
- Solanki, Ranjan
- Solomon, Yonatan
- Soriano, Joan B
- Sreeramareddy, Chandrashekhar T
- Steiropoulos, Paschalis
- Swain, Chandan Kumar
- Tabuchi, Takahiro
- Tampa, Mircea
- Tat, Nathan Y
- Teklay, Gebrehiwot
- Tessema, Belay
- Thangaraju, Pugazhenthan
- Thapar, Rekha
- Toma, Temesgen Mohammed
- Tram, Khai Hoan
- Udoakang, Aniefiok John
- Umar, Tungki Pratama
- Umeokonkwo, Chukwuma David
- Vahabi, Seyed Mohammad
- Vaithinathan, Asokan Govindaraj
- Varthya, Shoban Babu
- Wang, Ziyue
- Westerman, Ronny
- Wonde, Tewodros Eshete
- Yaghoubi, Sajad
- Yi, Siyan
- Yiğit, Vahit
- Yon, Dong Keon
- Yonemoto, Naohiro
- Yu, Chuanhua
- Zakham, Fathiah
- Zangiabadian, Moein
- Zeukeng, Francis
- Zhang, Haijun
- Zhao, Yang
- Zielińska, Magdalena
- Salomon, Joshua A
- Naghavi, Mohsen
- Vos, Theo
- Hay, Simon I
- Murray, Christopher J L
- Kyu, Hmwe Hmwe
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2024-07
- Volume
- 24
- Issue
- 7
- Pages
- 698-725
- ISSN
- 1473-3099 (ISSN-L)
- PMC
- PMC11187709
- OpenAlex
- W4392970825
- Semantic Scholar
- d707a077d18b9cdef721866ce35d1deaf6b2d7df
- Cited by
- 146
- References
- 106
- Citations by year
- 2026: 54 · 2025: 70 · 2024: 21
- FWCI
- 50.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet Infectious Diseases (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- Charles Sturt University Research Output (CRO) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, cc-by)
- Teesside University Research Portal (Teesside University) (acceptedVersion, cc-by)
- St George's Online Research Archive (St George's University of London) (acceptedVersion)
- Pure (Coventry University) (acceptedVersion, cc-by)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- SHURA (Sheffield Hallam University Research Archive) (Sheffield Hallam University) (acceptedVersion)
- ResearchOnline - JCU (James Cook University) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion, cc-by)
- AJOU Open Repository (Ajou University) (submittedVersion)
- Kocaeli Üniversitesi - AVESİS (submittedVersion)
- eCommons - AKU (Aga Khan University) (submittedVersion)
- National University of Singapore (submittedVersion)
- Touro Scholar (Touro College) (submittedVersion)
- FedUni ResearchOnline (Federation University Australia) (submittedVersion, cc-by)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion, cc-by)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion, cc-by-nc-nd)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Työväentutkimus Vuosikirja (submittedVersion)
- Intellectum (Universidad de La Sabana) (submittedVersion, cc-by-nc-nd)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- ANU Open Research (Australian National University) (submittedVersion, cc-by)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by)
- Funders
- Bill & Melinda Gates Foundation
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › HIV, TB, and STIs Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- tuberculosis, End TB Strategy, age-specific mortality, tuberculosis incidence, HIV coinfection, smoking, alcohol consumption, diabetes mellitus, risk factors, COVID-19 pandemic impact, tuberculosis control, tuberculosis prevalence, tuberculosis incidence trends, population attributable fraction
- MeSH terms
- Global Burden of Disease, Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Risk Factors, Tuberculosis, Global Health, World Health Organization, HIV Infections, Incidence, Young Adult, Coinfection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021. https://app.cochat.ai/papers/10.1016/s1473-3099(24)00007-0
- The paper
- Ledesma, J. R., Ma, J., Zhang, M., Basting, A. V. L., Chu, H. T., Vongpradith, A., Novotney, A., LeGrand, K. E., Xu, Y. Y., Dai, X., Nicholson, S. I., Stafford, L. K., Carter, A., Ross, J. M., Abbastabar, H., Abdoun, M., Abdulah, D. M., Aboagye, R. G., Abolhassani, H., . . . Kyu, H. H. (2024). Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(24)00007-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.